News & Information | START In The News

Welcome to START’s News & Information page.  Here you'll find the latest news releases and articles about START. Take a moment to browse through some of the stories that have been written about START.

December 16th, 2013

San Antonio's START to open second clinical trials center in Spain

San Antonio Business Journal
By: W. Scott Bailey
START (South Texas Accelerated Research Therapeutics) is opening a second Phase I clinical trials center in Madrid, Spain. The new center will be located in Hospital Fundacin Jimnez Daz and led by Dr. Victor Moreno.
December 10th, 2013

START welcomes Dr. Dongmei Ji, Visiting Medical Oncologist from the Medical Center of Fudan University

Dr. Ji is participating in START's International Observership Program
December 3rd, 2013

South Texas Accelerated Research Therapeutics and MEDIAN Technologies Sign Collaborative Agreement

MEDIAN's Lesion Management Solutions (LMS) medical image management software will be used for image interpretation and management during Phase I oncology trials conducted by South Texas Accelerated Research Therapeutics (START)
October 22nd, 2013

Cancer Advances Seen at Oncologists Conference

1200 WOAI
By: Jim Forsyth
Dr. Anthony Tolcher, director of clinical research at San Antonio's START Center, one of the world's leading centers for Phase One cancer drug tests, says there are a number of very promising therapies being discussed at the Annual Meeting of the American Association for Cancer Research.
October 17th, 2013

START Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting

By: News Release
This is an outstanding accomplishment for any institution involved in clinical cancer research in the world and reflects the hard work of START researchers throughout the world," said STARTs director of clinical research, Anthony W. Tolcher, MD.
September 20th, 2013

Half of All Cancer Deaths Now 'Preventable'

1200 WOAI
By: Jim Forsyth
Tolcher says the number of cancer deaths in the coming decades, despite the large number of Americans in the dangerous cancer years of their fifties and sixties, will be sharply lower than the number who are dying today.
September 12th, 2013

START to team up with China's BGI Tech on San Antonio cancer genome project

San Antonio Business Journal
By: W. Scott Bailey
The ground-breaking cancer genome study is designed to link genetic alterations that underlie different cancers to detailed clinical outcomes. Such findings could enable scientists to pursue the development of targeted, personalized cancer treatments.
August 8th, 2013

START - South Texas Accelerated Research Therapeutics Video

START - South Texas Accelerated Research Therapeutics Video
June 24th, 2013

ACPU Announces the Keynote Speaker for Their 2013 Annual Meeting

pharmiweb.com
The Association of Clinical Pharmacology Units (ACPU) the home for the Clinical Pharmacology Unit community has announced that Dr. Greg Koski an internationally renowned leader for human clinical trial subject protection and clinical research quality and safety is the keynote speaker for the 2013 ACPU annual meeting.
June 14th, 2013

San Antonio's START to team up with UT-Austin on cancer-fighting initiative

San Antonio Business Journal
By: W. Scott Bailey
South Texas Accelerated Research Therapeutics (START) and The University of Texas at Austins Department of Nutritional Sciences have entered into a collaborative agreement initiating a new Phase I drug development fellowship program.
June 4th, 2013

OncoMed Pharmaceuticals Presents Phase 1 Data in Solid Tumor Patients for the First-in-Class Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5) at

Business Wire
By: 2013 ASCO Annual Meeting
Vantictumab is Tolerable and has Evidence of Anti-tumor Activity in Solid Tumor Study; Vantictumab is Advancing to Combination Phase 1b Studies in Selected Tumor Types in 2013
May 30th, 2013

START to present an impressive number of abstracts of Phase I clinical trials data at ASCO 2013

This is an outstanding accomplishment for any institution involved in clinical cancer research in the world and reflects the hard work of START researchers throughout the world," said STARTs director of clinical research, Anthony W. Tolcher, MD.
May 30th, 2013

FDA approves Mekinist which underwent early testing at START

For the second time in under 45 days, the FDA has either approved or given breakthrough status to a drug that underwent Phase I clinical trials/ early testing at START The first one, called lambrolizumab, last month was granted Breakthrough status, meaning that the drug is considered important and regulators may be able to skip the long drawn out process for approval. Lambrolizumab is a melanoma agent and was given to 34 San Antonio cancer patients with success. The second drug, Mekinist (trametinib), was one of two drugs to receive FDA approval yesterday (Tafinlar (dabrafenib) was the second). Mekinist is for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer. START was the only center in South Texas to work on it during the early studies.
May 16th, 2013

Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting

The Wall Street Journal
By: PRESS RELEASE
Anthony Tolcher, M.D.will present "Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma."
April 25th, 2013

Melanoma Drug, First Tested at San Antonio's START Center, Granted 'Breakthrough' Status

WOAI
By: Jim Forsyth
The U.S. Food and Drug Administration has granted 'breakthrough' status to a melanoma drug first tested at San Antonio's START, putting it on the fast track for approval, 1200 WOAI news reports.
April 16th, 2013

Breast Cancer Public Service Announcement

March 7th, 2013

OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic

Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with advanced, refractory solid tumors. OMP-52M51, OncoMeds fifth product candidate, entered clinical testing in hematologic cancers in December 2012 and is now also being tested in patients with selected solid tumors. OMP-52M51 is a proprietary monoclonal antibody that targets the Notch1 receptor.